In Vivo Versus Augmented Reality Exposure for Small Animal Phobia

Status Completed

Clinical Trial Summary

The aim of this study is to explore the differential efficacy of in vivo exposure versus augmented reality exposure in the treatment of specific phobia (small animals).

The hypothesis is: There will not be significant statistical differences in the efficacy of in vivo exposure therapy versus augmented reality exposure in the treatment of specific phobia (small animals).

Clinical Trial Description

Among anxiety disorders, specific phobias are highly prevalent (around 7.2% and 11.3% in the general population). Cockroach or spider phobia is a type of specific phobia, animal type. The gold standard for the treatment of specific phobia (included small animal phobia) is in vivo exposure. Most phobia sufferers (60-80%) never seek treatment. Besides, not all patients benefit from in vivo exposure, given that an important amount of them do not accept the intervention or drop out (around 25%) when they are informed about the intervention procedure.

Information and Communication Technologies (ICT) like Virtual Reality (VR) and Augmented Reality (AR) are pioneer applications that can improve treatment adherence and acceptance. There exist some studies offering preliminary evidence of the efficacy of AR for the treatment of small animal phobia. However, there are not any controlled study exploring the differential efficacy of ICT-based exposure interventions versus in vivo exposure. In the present study the differential efficacy of AR exposure versus in vivo exposure for the treatment of small animal phobia is explored with a between subject randomized controlled trial. A pre-treatment assessment will be conducted in order to establish the diagnosis and evaluate the main outcome measures. All participants will receive an intensive exposure session following Öst guidelines, (in vivo exposure in one experimental condition and AR exposure in the other experimental condition). After the treatment a post-treatment assessment will be carried out as well as follow-up assessments at 3- and 12-month after treatment completion. ;

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment

Related Conditions & MeSH terms

Phobic Disorders

Clinical Trial Details

NCT number	NCT01361074
Study type	Interventional
Source	Universitat Jaume I
Contact
Status	Completed
Phase	N/A
Start date	January 2011
Completion date	January 2013

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01963806` - ACT-smart: Smartphone-supplemented iCBT for Social Phobia and/or Panic Disorder	N/A
Completed	`NCT00121069` - Study of Escitalopram in the Treatment of Specific Phobia	Phase 2/Phase 3
Recruiting	`NCT03653923` - Neurophysiological Correlates of Exposition Therapy in Spider Phobia	N/A
Completed	`NCT00184106` - RCT of Cognitive Therapy, Paroxetine, Combined CT and Paroxetine and Placebo	Phase 4
Completed	`NCT00051220` - Treatment for Specific Phobias in Children	Phase 1/Phase 2
Completed	`NCT02387047` - Validity of a Self-administered Questionnaire to Screen Phobia of Falling in the Elderly	N/A
Completed	`NCT02310152` - Explanatory Clinical Trial of a Novel Parent Intervention for Childhood Anxiety (SPACE)	N/A
Completed	`NCT00000370` - Treatment of Social Phobia	N/A
Completed	`NCT03012035` - The Role of Treatment Expectation in Exposure Training With Spider Fearful Participants	N/A
Completed	`NCT02007694` - Noradrenergic Manipulation and Virtual Reality Exposure Therapy in Phobic Participants	Phase 2/Phase 3
Active, not recruiting	`NCT03188575` - Effectiveness & Cost-effectiveness of Internet-delivered Interventions for Depression and Anxiety Disorders in IAPT	N/A
Completed	`NCT02432703` - A Safety and Efficacy Study of JNJ-42165279 in Participants With Social Anxiety Disorder	Phase 2
Terminated	`NCT01574014` - Glucocorticoid Treatment for Social Phobia	Phase 2
Completed	`NCT00734422` - Facilitation of Fear Extinction With Yohimbine Hydrochloride in Phobic Participants	Phase 2/Phase 3
Not yet recruiting	`NCT02336802` - Threat-Avoidance Learning in Anxiety Patients	N/A
Completed	`NCT00104195` - A Research Study of How Teens With and Without an Anxiety Disorder Make Decisions	Phase 1
Completed	`NCT00035412` - St. John's Wort Versus Placebo in Social Phobia	Phase 2
Completed	`NCT00128401` - Use of an Antibiotic as an Enhancer for the Treatment of Social Phobia	Phase 2
Recruiting	`NCT02020824` - Virtual Reality and Concept of Control in the Treatment of Acrophobia	N/A
Terminated	`NCT01623583` - Effect of Including Synera® in Discussions on Dialysis Access Conversion in Patients With Needle Phobias	Phase 4

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

In Vivo Versus Augmented Reality Exposure for Small Animal Phobia — VARESAP

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms